Realising the potential of correlates of protection for vaccine development, licensure and use: short summary

Deborah F King; Helen Groves; Charlie Weller; Ian Jones; Jakob P Cramer; Peter B Gilbert; David Goldblatt; Marion F Gruber; Beate Kampmann; Diadié Maïga; Marcela F Pasetti; Stanley A Plotkin; Alexander Precioso; Liya Wassie; Frederick Wittke; David C Kaslow

doi:10.1038/s41541-024-00872-6

Realising the potential of correlates of protection for vaccine development, licensure and use: short summary

NPJ Vaccines. 2024 Apr 29;9(1):82. doi: 10.1038/s41541-024-00872-6.

Authors

Deborah F King¹, Helen Groves², Charlie Weller², Ian Jones³, Jakob P Cramer⁴, Peter B Gilbert⁵, David Goldblatt⁶, Marion F Gruber⁷, Beate Kampmann⁸, Diadié Maïga⁹, Marcela F Pasetti¹⁰, Stanley A Plotkin¹¹, Alexander Precioso¹², Liya Wassie¹³, Frederick Wittke¹⁴, David C Kaslow^{15

16}

Affiliations

¹ Wellcome, 215 Euston Road, London, NW1 2BE, UK. d.king@wellcome.org.
² Wellcome, 215 Euston Road, London, NW1 2BE, UK.
³ WHO consultant, Jinja Publishing Ltd, London, UK.
⁴ Coalition for Epidemic Preparedness Innovations (CEPI), 215 Euston Road, London, NW1 2BE, UK.
⁵ Vaccine Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁶ Great Ormond Street Institute of Child Health, University College London, London, UK.
⁷ International AIDS Vaccine Initiative (IAVI), 125 Broad Street, New York, NY, 10004, USA.
⁸ London School of Hygiene & Tropical Medicine (LSHTM) Keppel Street, London, WC1E 7HT, United Kingdom.
⁹ World Health Organization (WHO) - Regional Office for Africa, Cité du Djoué, P.O.Box 06, Brazzaville, Republic of Congo.
¹⁰ Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
¹¹ University of Pennsylvania, Philadelphia, PA, USA.
¹² Instituto Butantan1500, Vital Brasil Avenue, Butantã, São Paulo, SP, 05503900, Brazil.
¹³ Armauer Hansen Research Institute, Jimma Road, ALERT Campus, Addis Ababa, Ethiopia.
¹⁴ MSD, The Circle 66, Zürich, CH, Switzerland.
¹⁵ PATH 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
¹⁶ US FDA, Seattle, WA, 98121, USA.

Abstract

On 27–29^th of September 2022, Wellcome convened an international multi-stakeholder workshop to discuss the use of Correlates of Protection (CoP) to accelerate vaccine development, the hybrid format meeting was attended by 80 delegates including developers, manufacturers, regulators, public health officials and policy-makers from 17 countries, including 7 LMIC’s.

Grants and funding

WT_/Wellcome Trust/United Kingdom